Cancer associated thrombosis in pediatric patients

Barg, Assaf Arie; Kenet, Gili

doi:10.1016/j.beha.2022.101352

Cited by 5 publications

(6 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their study has opposing results to ours for thrombosis, observing a 5% incidence of these events in pediatric population defined as 0–18 and a 34% in adults 24 . Thrombosis and hemorrhage are complex side effects with various risk factors, like chemotherapy treatment, central lines present and type of central line, patient characteristics, tumor factors, biomarkers, and so forth 25,26 . Presumably, in our population, most risk factors are similar (central line, treatment, and cancer) but were not all accounted in our model and our lack of numbers could account for our inconclusive findings.…”

Section: Discussioncontrasting

confidence: 74%

“…24 Thrombosis and hemorrhage are complex side effects with various risk factors, like chemotherapy treatment, central lines present and type of central line, patient characteristics, tumor factors, biomarkers, and so forth. 25,26 Presumably, in our population, most risk factors are similar (central line, treatment, and cancer) but were not all accounted in our model and our lack of numbers could account for our This study does present some limitations. The total number of events and the risk of accuracy bias by collecting information through chart review as a retrospective study cannot be discounted.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

The association of age and adverse events of PEG‐asparaginase in a pediatric tertiary care hospital; a retrospective review

Abbott

Claveau

Tang

et al. 2022

European J of Haematology

View full text Add to dashboard Cite

Background: Pediatric patients have a better survival rate for lymphoid malignancies than adolescents and young adult patients (AYA) and current evidence suggests that asparaginase plays a role in improved response to treatment. This study aimed to evaluate if increasing age as a continuous variable demonstrated increasing toxicities to PEG-asparaginase (PEG-ASP) for those patients treated at a tertiary care pediatric hospital.Methods: A retrospective chart review from 2007 to 2017 was conducted in the pediatric population at the Children's Hospital of Eastern Ontario (CHEO).Patients having received PEG-ASP were included. Event incidence and risk related to age at diagnosis were assessed through parameter estimates and Wald chi-square analysis.Results: In total, 75 adverse events were observed: 34/186 (18.3%) experienced allergic reactions, 8/186 (4.3%) pancreatitis, 31/186 (16.7%) thrombosis, and 2/186 (1.1%) hemorrhage. One hundred and eighty two patients had complete information for inclusion in our model. A correlation between age at diagnosis and higher risk of allergic reaction (p < .001) and pancreatitis (p < .035) was observed. Conclusion:Allergic reaction and pancreatitis following administration of PEG-ASP have a higher risk of occurrence as age of diagnosis increases up to 18 years of age. This includes the lower limit of traditionally defined AYA population of 15-39 and warrants precaution as PEG-ASP is included in older populations treatment regimens at pediatric centers.

show abstract

Section: Discussioncontrasting

confidence: 74%

Section: Discussionmentioning

confidence: 91%

The association of age and adverse events of PEG‐asparaginase in a pediatric tertiary care hospital; a retrospective review

Abbott

Claveau

Tang

et al. 2022

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…Cancer is a well‐known risk factor for thromboembolic events, especially in adults. Although thrombosis is relatively rare in the pediatric age group, it is reported that the frequency in the pediatric population is increased 1 . The diagnoses of leukemia and lymphoma are known as independent risk factors in patients with thrombosis, in which venous thromboembolism is predominant 2 .…”

Section: Introductionmentioning

confidence: 99%

“…Although thrombosis is relatively rare in the pediatric age group, it is reported that the frequency in the pediatric population is increased. 1 The diagnoses of leukemia and lymphoma are known as independent risk factors in patients with thrombosis, in which venous thromboembolism is predominant. 2 The estimated incidence of thrombosis in patients with leukemia has been reported in a fairly wide range, 5%-70%.…”

Section: Introductionmentioning

confidence: 99%

Central nervous system thrombosis in pediatric acute lymphoblastic leukemia in Turkey: A multicenter study

Güzelküçük¹,

Karapınar

Gelen

et al. 2023

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background: In patients with acute lymphoblastic leukemia (ALL), the risk of thromboembolism increases due to hemostatic changes secondary to the primary disease and due to treatment-related factors. In this multicenter study, we aimed to research the frequency of central nervous system (CNS) thrombosis occurring during treatment, hereditary and acquired risk factors, clinical and laboratory features of patients with thrombosis, treatment approaches, and thrombosis-related mortality and morbidity rates in pediatric ALL patients. Procedure: Pediatric patients who developed CNS thrombosis during ALL treatment from 2010 to 2021 were analyzed retrospectively in 25 different Pediatric Hematology Oncology centers in Türkiye. The demographic characteristics of the patients, symptoms associated with thrombosis, the stage of the leukemia treatment during thrombosis, the anticoagulant therapy applied for thrombosis, and the final status of the patients recorded through electronic medical records were determined.Results: Data from 70 patients with CNS thrombosis during treatment, out of 3968 pediatric patients with ALL, were reviewed. The incidence of CNS thrombosis was 1.8% (venous: 1.5 %; arterial: 0.03%). Among patients with CNS thrombosis, 47 had the event in the first 2 months. Low molecular weight heparin (LMWH) was the most commonly used treatment with a median of 6 months (min-max: 3-28 months). No treatment-related complications occurred. Chronic thrombosis findings occurred in four patients (6%). In five (7%) patients who developed cerebral vein thrombosis, neurological sequelae (epilepsy and neurological deficit) remained. One patient died related to thrombosis, and the mortality rate was 1.4%. Conclusion:Cerebral venous thrombosis and, less frequently, cerebral arterial thrombosis may develop in patients with ALL. The incidence of CNS thrombosis is higher during induction therapy than during other courses of treatment. Therefore, patients receiving induction therapy should be monitored carefully for clinical findings suggestive of CNS thrombosis.

show abstract

“…The prevalence of cancer-associated thrombosis varies from up to 16% of symptomatic to 40% of asymptomatic TE. [ 8 ] A population-based cohort study showed that the absolute incidence of venous thromboembolism (VTE) in children with cancer was 1.52 per 1000 person-years, while those without cancer had only 0.06 per 1000 person-years, with a risk ratio of 28.3. [ 8 ] The incidence of arterial thrombosis in children with cancer is far lower than that of venous thrombosis.…”

Section: Introductionmentioning

confidence: 99%

Right femoral vein and right dorsal artery thrombosis in childhood acute myeloid leukemia: A case report

Ni,

Chen,

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: It is rare for newly diagnosed (de novo) or newly treated acute myeloid leukemia (AML) complicated with thrombotic complications, especially combined arterial and venous thrombosis. Methods: We reported a 13-year-old boy diagnosed with AML and leukocytosis, who developed right femoral vein and right dorsal artery thrombosis during chemotherapy. After treatment with low molecular weight heparin, diosmin, and alprostadil, symptoms were relieved. Unfortunately, the child suffered from coagulopathy afterward, which was unexpectedly caused by vitamin K deficiency. Results: After supplementation with vitamin K and prothrombin complex concentrate, coagulation function recovered. Conclusion: For childhood AML patients with high thrombotic risks, close monitoring during anticoagulant treatment was necessary. Concomitantly, we should be alert to past medication history and combined medication use, especially those that may lead to vitamin K deficiency, secondary bleeding, and coagulation disorders. Rational use of antibiotics, anticoagulants, and antitumor drugs must be guaranteed.

show abstract

Cancer associated thrombosis in pediatric patients

Cited by 5 publications

References 58 publications

The association of age and adverse events of PEG‐asparaginase in a pediatric tertiary care hospital; a retrospective review

The association of age and adverse events of PEG‐asparaginase in a pediatric tertiary care hospital; a retrospective review

Central nervous system thrombosis in pediatric acute lymphoblastic leukemia in Turkey: A multicenter study

Right femoral vein and right dorsal artery thrombosis in childhood acute myeloid leukemia: A case report

Contact Info

Product

Resources

About